Suvretta Capital Management Increases Stake in Benitec Biopharma Inc.

Summary

Suvretta Capital Management LLC increased its holdings in Benitec Biopharma Inc. (NASDAQ: BNTC) by 1.5% in the fourth quarter, now holding 8,960,009 shares, making it the fifth-largest holding in the company. This investment accounts for 3.9% of Suvretta’s portfolio, valued at approximately $113.17 million. The stock opened at $13.60, with a market capitalization of $318.93 million and a P/E ratio of -9.01. Analysts have unanimously rated it as ‘buy’ with an average target price of $24.71.Market Beat

Impact Analysis

The event is at the company level, focusing on Suvretta Capital Management LLC’s increased investment in Benitec Biopharma Inc. This move is significant as it indicates confidence in the company’s potential, possibly due to upcoming innovations or market prospects in its sector. First-order effects include a potential price increase in Benitec Biopharma’s stock due to increased demand and positive sentiment from institutional investors. Second-order effects may involve increased interest from other institutional investors, potentially driving further stock appreciation. Investment opportunities for individuals might include buying into Benitec Biopharma (BNTC) to capitalize on the anticipated stock appreciation, considering the current ‘buy’ rating and target price set by analysts. However, risks include the company’s negative P/E ratio, suggesting current financial challenges that investors should monitor closely.Market Beat